[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版). 肝脏,2015,20:2-16.
[2] Su TH,Hu TH,Chen CY,et al. Four-year entecavir therapy reduces hepatocellular carcinoma,cirrhotic events and mortality in chronic hepatitis B patients.Liver Int,2016,36:1755-1764.
[3] Wang BQ,Wang YL,Shi KQ. Four-year entecavir therapy reduces hepatocellular carcinoma,cirrhotic events and mortality in chronic hepatitis B patients. Liver Int,2017,37:309-310.
[4] Su TH,Kao JH. Response to four-year entecavir therapy reduces hepatocellular carcinoma,cirrhotic events and mortality in chronic hepatitis B patients. Liver Int,2017,37:310-311.
[5] 陆荫英,李晶. 《慢性乙型肝炎防治指南(2015年版)》解读之:HBV感染相关HCC的随访监测. 中国肝脏病杂志(电子版),2015,3:36-39. |
